CTNNB1

Chr 3AD

catenin beta 1

Also known as: CTNNB, EVR7, MRD19, NEDSDV, armadillo

The protein encoded by this gene is part of a complex of proteins that constitute adherens junctions (AJs). AJs are necessary for the creation and maintenance of epithelial cell layers by regulating cell growth and adhesion between cells. The encoded protein also anchors the actin cytoskeleton and may be responsible for transmitting the contact inhibition signal that causes cells to stop dividing once the epithelial sheet is complete. Finally, this protein binds to the product of the APC gene, which is mutated in adenomatous polyposis of the colon. Mutations in this gene are a cause of colorectal cancer (CRC), pilomatrixoma (PTR), medulloblastoma (MDB), and ovarian cancer. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Aug 2016]

Primary Disease Associations & Inheritance

Colorectal cancer, somaticMIM #114500
Exudative vitreoretinopathy 7MIM #617572
AD
Hepatocellular carcinoma, somaticMIM #114550
Medulloblastoma, somaticMIM #155255
Neurodevelopmental disorder with spastic diplegia and visual defectsMIM #615075
AD
Ovarian cancer, somaticMIM #167000
Pilomatricoma, somaticMIM #132600
UniProtPilomatrixoma
UniProtMesothelioma, malignant
UniProtVitreoretinopathy, exudative 7
627
ClinVar variants
158
Pathogenic / LP
1.00
pLI score· haploinsufficient
12
Active trials
Clinical SummaryCTNNB1
🧬
Gene-Disease Validity (ClinGen)
CTNNB1-related neurodevelopmental disorder and/or vitreoretinopathy · ADDefinitive

Definitive — sufficient evidence for diagnostic panels

Population Constraint (gnomAD)
Highly constrained gene — heterozygous loss-of-function variants are very rare in the population (pLI 1.00). One damaged copy is likely sufficient to cause disease.
📋
ClinVar Variants
158 Pathogenic / Likely Pathogenic· 237 VUS of 627 total submissions
💊
Clinical Trials
12 active or recruiting trials — potential therapeutic options may be available

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Dual constrained — LoF & missense intolerant
LoF Constraint?LOEUF (Loss-of-function Observed/Expected Upper bound Fraction) is the upper bound of the 90% CI for LoF OE — the preferred gnomAD v4 metric. Lower = more intolerant to LoF. LOEUF < 0.35 = highly constrained.
0.13LOEUF
pLI 1.000
Z-score 5.46
OE 0.03 (0.010.13)
Highly constrained

Among the most LoF-intolerant genes (~top 3%)

Missense Constraint?Missense Z-score: standard deviations fewer missense variants observed vs. expected. Z > 3.09 (p < 0.001) = gene does not tolerate missense variation. OE missense < 0.6 is also considered constrained.
3.85Z-score
OE missense 0.47 (0.420.53)
199 obs / 421.1 exp
Constrained

Highly missense-constrained (top ~0.1%)

Observed / Expected Ratios?Shaded band = 90% confidence interval. Vertical tick = point estimate. Grey threshold line = gnomAD constraint cutoff for that variant class.
LoF OE?Ratio of observed to expected LoF variants. Upper CI bound (LOEUF) ≤ 0.35 = strong LoF constraint signal.0.03 (0.010.13)
00.351.4
Missense OE?Ratio of observed to expected missense variants. OE ≤ 0.6 = fewer missense variants than expected by chance.0.47 (0.420.53)
00.61.4
Synonymous OE?Control metric — synonymous variants are largely neutral and expected near OE = 1.0. Significant deviation may indicate annotation issues.0.99
01.21.6
LoF obs/exp: 1 / 36.7Missense obs/exp: 199 / 421.1Syn Z: 0.14

ClinVar Variant Classifications

627 submitted variants in ClinVar

Classification Summary

Pathogenic113
Likely Pathogenic45
VUS237
Likely Benign201
Benign16
Conflicting15
113
Pathogenic
45
Likely Pathogenic
237
VUS
201
Likely Benign
16
Benign
15
Conflicting

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
63
5
44
1
113
Likely Pathogenic
17
14
14
0
45
VUS
2
214
17
4
237
Likely Benign
0
4
94
103
201
Benign
0
0
13
3
16
Conflicting
15
Total82237182111627

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

Protein Context — Lollipop Plot

CTNNB1 · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

Gene2Phenotype Curations

CTNNB1-related exudative vitreoretinopathy

definitive
ADLoss Of FunctionAbsent Gene Product
Eye
G2P ↗

CTNNB1-related intellectual developmental disorder

definitive
ADLoss Of FunctionAbsent Gene Product
Dev. Disorders
G2P ↗

Gene2Phenotype curations · DECIPHER consortium patient cohort (public variants) · deciphergenomics.org

OMIM — Genotype-Phenotype Relationships

1 OMIM entry

CATENIN, BETA-1; CTNNB1
MIM #116806 · *

Colorectal cancer, somatic

MIM #114500

Molecular basis of disorder known

Exudative vitreoretinopathy 7

MIM #617572

Molecular basis of disorder known

Autosomal dominant

Hepatocellular carcinoma, somatic

MIM #114550

Molecular basis of disorder known

Medulloblastoma, somatic

MIM #155255

Molecular basis of disorder known

Neurodevelopmental disorder with spastic diplegia and visual defects

MIM #615075

Molecular basis of disorder known

Autosomal dominant

Ovarian cancer, somatic

MIM #167000

Molecular basis of disorder known

Pilomatricoma, somatic

MIM #132600

Molecular basis of disorder known

📖
GeneReview available — CTNNB1
Authoritative clinical overview · NCBI Bookshelf · Recommended first read
Open GeneReview ↗
Clinical Literature
Landmark / reviewRecent case evidence
Key Publications
Landmark & review papers · by relevance
PubMed
Molecular and histological correlations in liver cancer.
Calderaro J et al.·J Hepatol
2019Review
Top 10 resultsSearch PubMed ↗

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

16P11.2 Deletion Syndrome16p11.2 Duplications1Q21.1 Deletion

Online Study of People Who Have Genetic Changes and Features of Autism: Simons Searchlight

RECRUITING
NCT01238250Simons SearchlightStarted 2010-10
Gastric CancerHealthy

Preliminary Experimental Study on Key Technologies for Early Screening of Gastric Cancer

RECRUITING
NCT05991947Zhejiang Cancer HospitalStarted 2021-03-01
No intervention
Desmoid FibromatosisRecurrent Desmoid FibromatosisUnresectable Desmoid Fibromatosis

A Study of a New Drug, Nirogacestat, for Treating Desmoid Tumors That Cannot be Removed by Surgery

ACTIVE NOT RECRUITING
NCT04195399Phase PHASE2Children's Oncology GroupStarted 2020-10-07
Biospecimen CollectionComputed TomographyEchocardiography Test
Post Traumatic Stress DisorderComplex Posttraumatic Stress DisorderStress

Building Resilience at Schools: Emotional and Biological Assessment and Treatment of Traumatic Stress

RECRUITING
NCT05701111Phase NAStanford UniversityStarted 2024-02-23
Start with the Heart StudentsStart with the Heart TeachersCue Centered Therapy Counselors
CTNNB1 Neurodevelopmental Syndrome

Gene Replacement Therapy for Treatment of Paediatric Patients With CTNNB1 Neurodevelopmental Syndrome

RECRUITING
NCT07270549Phase PHASE1, PHASE2CTNNB1 FoundationStarted 2025-11-01
Urbagen gene addition therapySirolimusMethylprednisolone (Corticosteroid)
Craniopharyngioma, Child

Prospective Pilot Study Identifying Clinically Relevant Biological Targets for Medical Therapy

ENROLLING BY INVITATION
NCT03610906University of Colorado, DenverStarted 2019-03-12
Tumor and Blood Specimens
Advanced Hepatocellular CarcinomaMetastatic Hepatocellular CarcinomaStage III Hepatocellular Carcinoma AJCC v8

Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin, The SAPHIRE Trial

RECRUITING
NCT06811116Phase PHASE1, PHASE2National Cancer Institute (NCI)Started 2025-11-17
Biospecimen CollectionCabozantinib S-malateImaging Procedure
Colorectal Cancer

ASPirin Intervention for the REDuction of Colorectal Cancer Risk

ACTIVE NOT RECRUITING
NCT02394769Phase NAMassachusetts General HospitalStarted 2015-07-06
AspirinPlacebo for Aspirin
Lung Cancer

Feasibility of Targeted Bronchial Washing for Molecular Testing by Next Generation Sequencing in Early-stage Lung Cancer

ACTIVE NOT RECRUITING
NCT06301295Phase NAPusan National University HospitalStarted 2024-05-29
Ultarthin bronchoscopy with intratumoral washing
Unresectable Colorectal Neoplasm Metastasis

Study of a Tankyrase Inhibitor RK-582 for Patients With Unresectable Metastatic Colorectal Cancer

RECRUITING
NCT06853496Phase PHASE1Eiji ShinozakiStarted 2025-03-13
RK-582
Advanced Hepatocellular CarcinomaMetastatic Hepatocellular Carcinoma

A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma

RECRUITING
NCT06600321Phase PHASE1Alnylam PharmaceuticalsStarted 2024-12-30
ALN-BCATPembrolizumab
Aggressive Fibromatosis

National Clinical-biological Prospective Cohort of Incident Cases of Aggressive Fibromatosis (ALTITUDES)

ACTIVE NOT RECRUITING
NCT02867033Phase NACentre Oscar LambretStarted 2016-03-22
biopsybiobank constitutionColoscopy